EBOS Group

EBOS Group

EBOS Group traces its origin to 1922 when it was founded in Christchurch as a small pharmaceutical wholesaler. Over a century, the company expanded through organic growth and disciplined acquisitions, establishing itself as the preeminent healthcare logistics and distribution platform in Australasia. The firm supplies medical consumables, branded pharmaceuticals, over-the-counter products, and institutional healthcare equipment to hospitals, community pharmacies, and aged-care providers. The founding family and long-tenured management have overseen its transformation into a publicly listed company on both the New Zealand Exchange and the Australian Securities Exchange. The company's growth strategy combines distribution scale with vertical integration into higher-margin adjacent sectors. Its healthcare segment provides third-party logistics, wholesale distribution, and institutional supply to more than 3,000 pharmacies and hospitals across the region. In animal care, EBOS owns the leading veterinary distribution networks in Australia and New Zealand, supplying over 2,000 veterinary clinics with products ranging from parasiticides to surgical equipment (per public record). Confirmed brand assets include BlackHawk premium pet food, the Lyppard Australia veterinary wholesale platform, and medical device distribution agreements with global manufacturers. EBOS Group employs several thousand staff and generates revenues exceeding NZD 10 billion annually, placing it among the largest companies on the NZX 50 (per the firm's official communications, 2023). The firm operates from main offices in Christchurch, Auckland, Sydney, Melbourne, and a growing footprint in Singapore. The leadership team, helmed by CEO John Cullity, has steered more than a decade of uninterrupted earnings growth. February 2024: EBOS completed the acquisition of Superior Pet Food Co., expanding its own-brand pet nutrition manufacturing capacity (per the firm, February 2024). Unlike a traditional single-family office, EBOS operates as a publicly listed holding company with deep family and institutional ownership, trading on dual exchanges. This hybrid structure provides permanent capital for long-horizon healthcare infrastructure investments while maintaining public-market liquidity for shareholders. The governance model—blending a professional C-suite with a board chaired by Elizabeth Coutts—represents an uncommon architecture in the typically private world of family-controlled distribution empires, offering co-investors and allocators a transparent vehicle into core healthcare logistics.